Videos

Experts in stem cell transplantation review the background of graft-versus-host disease and discuss 3 clinical cases and individualized treatment approaches.

Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.

Eric A. Klein, MD, discusses the role of genomic testing in patients with prostate cancer and how these findings can impact treatment decisions.

Suresh Ramalingam, MD, FASCO, discusses the key takeaways regarding the toxicities observed in the phase 3 CheckMate 227 clinical trial, which evaluated immunotherapeutic agents nivolumab plus ipilimumab as treatment of patients with non–small cell lung cancer.

Saad Z. Usmani, MD, discusses the phase 2 SWOG 1211 trial investigating bortezomib, lenalidomide, and dexamethasone with or without elotuzumab for patients with newly diagnosed, high-risk multiple myeloma.

Sylvia Adams, MD, discusses the synergy between anti-CTLA4 and anti-PD-L1 antibodies as treatment of patients with breast cancer.

Julie Gralow, MD, discusses the use of patient-reported outcomes in the SWOG S1105 trial and different factors for patients with early-stage breast cancer on an aromatase inhibitor to see if they could predict who may be more likely to stop taking treatment early.

A discussion on the development of targeted therapies for the management of advanced cholangiocarcinoma, with consideration of multiple ongoing trials with notable outcomes.